Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?

被引：35

作者：

Bagchi, Shashwatee

Kempf, Mirjam C.

Westfall, Andrew O.

Maherya, Anastasiya

Willig, James

Saag, Michael S.

机构：

[1] Univ Alabama, Ctr AIDS Res, Dept Med, Sch Publ Hlth, Birmingham, AL 35294 USA

[2] Univ Alabama, Dept Epidemiol, Sch Publ Hlth, Birmingham, AL 35294 USA

[3] Univ Alabama, Dept Biostat, Sch Publ Hlth, Birmingham, AL 35294 USA

[4] Univ Alabama, Div Geog Med, Sch Publ Hlth, Birmingham, AL 35294 USA

[5] Univ Alabama, Dept Infect Dis, Sch Publ Hlth, Birmingham, AL 35294 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2007年 / 44卷 / 01期

关键词：

D O I：

10.1086/510072

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Although routine clinical markers are used routinely to determine the stage of human immunodeficiency virus (HIV) disease, their use in monitoring response to antiretroviral therapy is poorly defined. Selected clinical markers were evaluated for their ability to predict first-line antiretroviral therapy success. No clinically meaningful variables were identified that predicted virologic or immunological success, implying that the CD4(+) cell count and HIV type 1 RNA level data are required for optimal management of antiretroviral therapy.

引用

收藏

页码：135 / 138

页数：4

相关论文

共 12 条

[1] CD4(+) T-lymphocyte counts in HIV infection: Are European standards applicable to African patients? [J].

Anglaret, X ;

Diagbouga, S ;

Mortier, E ;

Meda, N ;

VergeValette, V ;

SyllaKoko, F ;

Cousens, S ;

Laruche, G ;

Ledru, E ;

Bonard, D ;

Dabis, F ;

VandePerre, P .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1997, 14 (04) :361-367

[2]

[Anonymous], 2003, SCAL ANT THER RES LT

[3] Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings [J].

Badri, M ;

Wood, R .

AIDS, 2003, 17 (04) :541-545

[4] TOTAL LYMPHOCYTE COUNT AS A PREDICTOR OF ABSOLUTE CD4+ COUNT AND CD4+ PERCENTAGE IN HIV-INFECTED PERSONS [J].

BLATT, SP ;

LUCEY, CR ;

BUTZIN, CA ;

HENDRIX, CW ;

LUCEY, DR .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (05) :622-626

[5] THROMBOCYTOPENIA IN PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - TREATMENT UPDATE [J].

GLATT, AE ;

ANAUD, A .

CLINICAL INFECTIOUS DISEASES, 1995, 21 (02) :415-423

[6] Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries [J].

Kumarasamy, N ;

Mahajan, AP ;

Flanigan, TP ;

Hemalatha, R ;

Mayer, KH ;

Carpenter, CCJ ;

Thyagarajan, SP ;

Solomon, S .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 (04) :378-383

[7] Changes in total lymphocyte count as a surrogate for changes in CD4 count following initiation of HAART: Implications for monitoring in resource-limited settings [J].

Mahajan, AP ;

Hogan, JW ;

Snyder, B ;

Kumarasamy, N ;

Mehta, K ;

Solomon, S ;

Carpenter, CCJ ;

Mayer, KH ;

Flanigan, TP .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 36 (01) :567-575

[8]

Post FA, 1996, QJM-MON J ASSOC PHYS, V89, P505

[9] Use of total lymphocyte count for monitoring response to antiretroviral therapy [J].

Schreibman, T ;

Friedland, G .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (02) :257-262

[10] Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings [J].

Spacek, LA ;

Griswold, M ;

Quinn, TC ;

Moore, RD .

AIDS, 2003, 17 (09) :1311-1317